Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34105064

about

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Update on the treatment of type 2 diabetes mellitus Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

P2860

Q26777529-DD2B3A4D-FB8A-4481-A97A-C865165B43EF Q28073342-EF3A61FF-E76F-46FC-9BAC-D54D5A9BBAEB Q33771405-01BAB6F2-0488-4479-A507-F1FD578D5DBA Q33845734-19BE8600-970D-4975-B4D8-E0521CCA19CA Q34726437-3386E112-6B8C-4939-9A61-955BEE8E5025 Q36867463-766CB9AD-7C98-4F77-B71B-039D04A26CB2 Q37456313-E468B41C-6E58-47F9-93B9-EA737B067212 Q38371524-89F26ED9-2BC9-4C01-AE2D-12A8D65C76EE Q38383470-62C12A44-FFDF-40F3-8EA5-CE023B5E9D4C Q38515085-AC85FC90-AE6C-489F-A588-F5A22B6F4F70 Q38573559-9728EC94-A21D-4505-B14C-EF84100044D9 Q38679997-E8C5F0D6-2656-47BD-9057-DB03BE05ABEC Q38798654-8F6A8126-6065-4A6A-9FB9-6E2E4230EA90 Q38990518-D30162FA-52F6-469A-83FA-F77927ED6192 Q42206175-C27892D1-E5E5-4F2D-A839-23C9DA2933F5 Q47260852-D88CDCFF-6187-41CF-A987-FC421F817236 Q47316565-7B96503D-13E1-4391-BC14-7175A88FFDD5 Q57222384-0A04904E-F897-49B9-8899-25E3F8673A75

P2860

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34105064

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@ast

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@en

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@nl

type

label

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@ast

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@en

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@nl

prefLabel

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@ast

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@en

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@nl

P1433

Q34105064-01C58B44-A9E2-4B1A-9EAB-1C7049664ECE

P1476

Q34105064-3AD7BD19-B548-4BA3-8017-2F95EA497DC9

P2093

Q34105064-03603058-23EC-4ED0-8B83-101BF9D2DF37

Q34105064-23AA5EF9-1C95-4548-8287-5D1D491E76FE

Q34105064-24044868-0712-41CA-9571-6C77DC1AECBC

Q34105064-4E196502-1C28-4527-9020-7144658A0679

Q34105064-6779F0B8-C1C6-46A0-9F41-38F8C560248C

Q34105064-73E3FF20-290C-4880-A17B-C352CEF5017D

Q34105064-764CDE17-07F8-4AC4-A98B-CF0F4ECEA516

Q34105064-C6E04BF6-F283-4F93-BFDF-592A47D4EC4B

Q34105064-D8B77B66-D398-4938-BA79-627BF144DEF4

P2860

Q34105064-093F1013-7676-4EED-B0E8-C5ED697C6A9F

Q34105064-0FEE0666-728B-4AED-89ED-558AA82601CF

Q34105064-13BD0298-7B2C-4DB2-A09A-7209FC45B66E

Q34105064-146DDF13-4BCE-4065-AA64-6F48283CA810

Q34105064-17FC1561-7592-4508-961E-BBE4AFD56318

Q34105064-1EC185C4-0521-4BF7-9EA7-D92663350D4C

Q34105064-1FA8FC15-F93F-42E5-849B-1AA57ECFD324

Q34105064-2B53F2AF-60D0-4C55-8F93-093FC10831C5

Q34105064-2D44AD77-3A46-4B1E-BD5A-C09DDF776FA3

Q34105064-2FFE4A63-CBE2-4A8E-8396-F3D4C7796D62

P304

Q34105064-0BC98A8C-B8E9-4F33-BDC9-A3CEB77D8BA7

P31

Q34105064-F96F3BA8-CBAE-4D40-8920-6DC9CD57ECF8

P356

Q34105064-4DA31685-8A91-48B4-A1FC-B37B802E9CC5

P407

Q34105064-D697072E-1551-41F0-90DD-1787D84E3C5C

P433

Q34105064-FCD3CEC7-2990-461F-AAEB-4DB81A0F19A0

P478

Q34105064-CF5EC730-EE21-4499-9415-BF2FAFE6811E

P50

Q34105064-1DE0D9C8-270A-444E-8084-7BFB3C9EF65C

P577

Q34105064-F9E0D9C8-A5A3-42C5-865E-81456985D1BE

P5875

Q34105064-71AC7AE8-2782-4143-9570-30562CF05F46

P698

Q34105064-E0C62DC4-78E2-4A9E-98C1-F52FC0466755

P921

Q34105064-7E3F5ACF-EF70-4447-8E83-143ECBD8F9AF

P932

Q34105064-156CC5AE-8726-47BB-8846-A97ABCB6C10D

P356

JOURNAL.PONE.0105638

P1433

P1476

Pharmacodynamic effects of can ...... patients with type 2 diabetes.

@en

P2093

Atalanta Ghosh

http://www.w3.org/2001/XMLSchema#string

Damayanthi Devineni

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Heike Spitzer

http://www.w3.org/2001/XMLSchema#string

Keith Demarest

http://www.w3.org/2001/XMLSchema#string

Linda Morrow

http://www.w3.org/2001/XMLSchema#string

Paul Rothenberg

http://www.w3.org/2001/XMLSchema#string

Sabine Arnolds

http://www.w3.org/2001/XMLSchema#string

Sue Sha

http://www.w3.org/2001/XMLSchema#string

P2860

Renal Na(+)-glucose cotransporters

Active sugar transport in health and disease

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Model predictive control of type 1 diabetes: an in silico trial

SGLT2 inhibition--a novel strategy for diabetes treatment.

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

P304

e105638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0105638

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Marcus Hompesch

P577

2014-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265135978

http://www.w3.org/2001/XMLSchema#string

P698

25166023

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4148334

http://www.w3.org/2001/XMLSchema#string